Selatogrel, the reversible and specific P2Y12 receptor antagonist, does not interfere with haemostasis

被引：0
|
作者：
Riederer, M. A. [1 ]
Crescence, L. [2 ]
Caroff, E. [1 ]
Hubler, F. [1 ]
Panicot-Dubois, L. [2 ]
Dubois, C. [2 ]
机构：
[1] Idorsia Pharmaceut Ltd, Allschwil, Switzerland
[2] Aix Marseille Univ, INSEAM 1263, INRAE 1260, C2VN, Marseille, France
来源：
EUROPEAN HEART JOURNAL | 2020年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3819 / 3819
页数：1
相关论文
共 50 条
  • [41] From ATP to AZD6140:: The discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis
    Springthorpe, Brian
    Bailey, Andrew
    Barton, Patrick
    Birkinshaw, Timothy N.
    Bonnert, Roger V.
    Brown, Roger C.
    Chapman, David
    Dixon, John
    Guile, Simon D.
    Humphries, Robert G.
    Hunt, Simon F.
    Ince, Francis
    Ingall, Anthony H.
    Kirk, Ian P.
    Leeson, Paul D.
    Leff, Paul
    Lewis, Richard J.
    Martin, Barrie P.
    McGinnity, Dermot F.
    Mortimore, Michael P.
    Paine, Stuart W.
    Pairaudeau, Garry
    Patel, Anil
    Rigby, Aaron J.
    Riley, Robert J.
    Teobald, Barry J.
    Tomlinson, Wendy
    Webborn, Peter J. H.
    Willis, Paul A.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (21) : 6013 - 6018
  • [42] Mind the Gap: Model-Based Switching from Selatogrel to Maintenance Therapy with Oral P2Y12 Receptor Antagonists
    Hsin, Chih-hsuan
    Dingemanse, Jasper
    Henrich, Andrea
    Bernaud, Corine
    Gehin, Martine
    Krause, Andreas
    BIOMOLECULES, 2023, 13 (09)
  • [43] The future of P2Y12 receptor antagonists
    Thomas, Mark R.
    Storey, Robert F.
    PLATELETS, 2015, 26 (05) : 392 - 398
  • [44] Development of a Multi-Kilogram-Scale Synthesis of AZD1283: A Selective and Reversible Antagonist of the P2Y12 Receptor
    Andersen, Soren M.
    Aurell, Carl-Johan
    Zetterberg, Fredrik
    Bollmark, Martin
    Ehrl, Robert
    Schuisky, Peter
    Witt, Anette
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2013, 17 (12) : 1543 - 1551
  • [45] Pharmacokinetics and pharmacodynamics of AZD6140, the first reversible oral P2Y12 receptor antagonist, administered with aspirin.
    Butler, K.
    Winter, H.
    Mitchell, P.
    Fox, J.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (09): : 1204 - 1204
  • [46] A Clopidogrel-Insensitive Inducible Pool of P2Y12 Receptors Contributes to Thrombus Formation: Inhibition by Elinogrel, a Direct-Acting, Reversible P2Y12 Antagonist
    Haberstock-Debic, Helena
    Andre, Patrick
    Mills, Scott
    Phillips, David R.
    Conley, Pamela B.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2011, 339 (01): : 54 - 61
  • [47] AZD6140.: Antiplatelet therapy, P2Y12 (P2T) receptor antagonist
    Owen, R. T.
    Serradell, N.
    Bolos, J.
    DRUGS OF THE FUTURE, 2007, 32 (10) : 845 - 853
  • [48] Thrombus remodelling by reversible and irreversible P2Y12 inhibitors
    Tunstromer, Kjersti
    Faxalv, Lars
    Larsson, Pia
    Lindahl, Tomas L.
    Boknas, Niklas
    PLATELETS, 2023, 34 (01)
  • [49] Molecular mechanism of action for reversible P2Y12 antagonists
    Liu, Haibo
    Ge, Hu
    Peng, Yong
    Xiao, Peigen
    Xu, Jun
    BIOPHYSICAL CHEMISTRY, 2011, 155 (2-3) : 74 - 81
  • [50] Ticagrelor: the first novel reversible P2Y12 inhibitor
    Htun, Wah Wah
    Steinhubl, Steven R.
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (02) : 237 - 245
12345